Our team

Seung-Hoon Lee, MD, PhD, FAHA
CEO
Dr. Seung-Hoon Lee leads the world’s first CDMO dedicated solely to nanomedicine. With a distinguished background in clinical medicine, translational research, and pharmaceutical development, he brings a deep understanding of the challenges in advancing nanoparticle-based therapeutics. He leads the company in delivering integrated, GMP-compliant solutions that help partners advance and scale nanoparticle-based therapeutics.

Bong Geun Cha, PhD
CTO
Dr. Bong Geun Cha, CTO and Director of the Corporate Research Institute at OmniParticles, is an expert in chemical engineering with a focus on nanomedicine. He holds a Ph.D. in Chemical Engineering from Sungkyunkwan University and has conducted research at Harvard University. At OmniParticles, he leads innovation and R&D, driving advancements in nanoparticle-based drug development and manufacturing.

Moon-Sun Choi, MPH
CMO
Moon-Sun Choi is a regulatory affairs specialist with over 18 years of experience. She has led regulatory strategies and clinical programs across multiple therapeutic areas at Celltrion, ensuring compliance with global health authorities. With extensive experience overseeing CROs, managing regulatory submissions, and navigating inspections, she provides expert regulatory support to streamline drug development and approval processes.
